MedPath

Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Recruiting
Conditions
Chronic Graft-versus-host Disease
Acute Graft-versus-host Disease
Chronic GVHD
Acute GVHD
Registration Number
NCT02611180
Lead Sponsor
Washington University School of Medicine
Brief Summary

Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells.

Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells.

To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
50
Inclusion Criteria
  • At least 18 years of age at enrollment
  • Willing and able to sign the informed consent
  • Current diagnosis/suspected diagnosis of acute skin GVHD OR Current diagnosis/suspected diagnosis of chronic skin GVHD
Exclusion Criteria
  • Known infection with Hepatitis B or C, HTLV, or HIV
  • Pregnant females

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Dendritic cell characteristicsUp to 2 years

* Both GVHD affected and unaffected skin sections will be analyzed by immunostaining and the types of cells and strains of skin microbiota present will be analyzed

* The different isolated DCs will be activated by different stimuli and will be characterized by gene (DNA, RNA sequencing or arrays) and multicolor flow cytometry analysis.

Genes and skin microbiota that correlate with dendritic cell functionUp to 2 years
Potential treatment targets as measured by deep sequencing or microarray analysisUp to 2 years
Antigen specific lymphocyte subset characteristicsUp to 2 years

* Both GVHD affected and unaffected skin sections will be analyzed by immunostaining and the types of cells and strains of skin microbiota present will be analyzed

* CD4+ and CD8+ T cells or other lymphocyte populations will be isolated from peripheral blood by fluorescence activated cell sorting. The DC subsets purified from the skin tissue will be used to stimulate these T cell populations. This will be followed by thorough characterization of the charged T cell populations by a variety of methods. These will include assays to measure proliferation, gene array analysis cytokine secretion and other functions of the charged T cells.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Eynav Klechevsky, Ph.D.
Principal Investigator
Caroline Bumb
Contact
314-362-7249
cbumb@wustl.edu
Mark Schroeder, M.D.
Sub Investigator
Camille Abboud, M.D.
Sub Investigator
Amanda Cashen, M.D.
Sub Investigator
John F DiPersio, M.D., Ph.D.
Sub Investigator
Todd Fehniger, M.D., Ph.D.
Sub Investigator
Armin Ghobadi, M.D.
Sub Investigator
Amy Musiek, M.D.
Sub Investigator
Iskra Pusic, M.D.
Sub Investigator
Keith Stockerl-Goldstein, M.D.
Sub Investigator
Geoffrey Uy, M.D.
Sub Investigator
Ravi Vij, M.D.
Sub Investigator
Matthew Walter, M.D.
Sub Investigator
John Welch, M.D., Ph.D.
Sub Investigator
Peter Westervelt, M.D., Ph.D.
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.